Please assess the completion status of the following clinical trial:

Trial Title: Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women, 18-70 years of age.~* Currently meet the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision (DSM-IV-TR) criteria for Major Depressive Disorder.~* The patient's current major depressive episode must be at least 8 weeks and no longer than 12 months in duration.~Exclusion Criteria:~* Women who are pregnant, women who will be breastfeeding during the study, and women of childbearing potential who are not practicing a reliable method of birth control.~* Patients with a history of meeting DSM-IV-TR criteria for any:~  * manic, hypomanic or mixed episode, including bipolar disorder and substance-induced manic, hypomanic, or mixed episode;~ * any depressive episode with psychotic or catatonic features;~ * panic disorder with or without agoraphobia;~ * obsessive-compulsive disorder;~ * schizophrenia, schizoaffective, or other psychotic disorder;~ * bulimia or anorexia nervosa;~ * presence of borderline personality disorder or antisocial personality disorder;~ * mental retardation, dementia, amnesia, or other cognitive disorders;~ * patients who are considered a suicide risk.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Dose-matched placebo (Type: PLACEBO_COMPARATOR): Participants received dose-matched placebo orally once daily for 9 weeks.
- Vilazodone (Type: EXPERIMENTAL): Participants received vilazodone orally once daily for 9 weeks, as follows: Week 1, 10 mg once a day; Week 2, 20 mg once a day; Weeks 3 to 8, 40 mg once a day; and Week 9 (down-taper period), 20 mg once a day for 4 days, then 10 mg once a day for 3 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).